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Gastric cancer.Abstract Ramucirumab is the recent addition to the list of monoclonal antibodies being tried in
various malignancies. It has been approved in non-small cell lung cancer, gastric cancer and col-
orectal cancer after progression of one or more line of therapies in the advanced setting. Though
randomized trials have shown beneﬁt, the cost effectiveness is questionable. Moreover, the beneﬁts
shown are marginal, putting a question mark over its clinical usage. This review summarizes the
latest evidence on ramucirumab.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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The challenge to offer prolongation of life in advanced cancers
remains an unending quest. This is the area where targeted
therapies might offer a welcomed respite. Ramucirumab
(IMC-112B) is new addition to the list of monoclonal antibod-
ies being tried in this subset of patients. It targets angiogenesis
and is advantageous due to its receptor selectivity with mini-
mal off target activity. Currently approved in second line set-
ting in gastric cancer, non-small cell lung cancer (NSCLC)
and colon cancer, it is ﬁnding application in myriad malignan-
cies. This review is an attempt to comprehensively sum-up
existing evidence on this drug.Chemical structure and mechanism of action
Ramucirumab is a fully human monoclonal antibody, IgG1
subtype [1]. It is a polypeptide molecule made of two heavy
chains and two light chains [2].
It binds the extracellular domain of vascular endothelial
growth factor receptor-2 (VEGFR-2), blocking interaction
between VEGFR-2 and its ligands (Fig. 1).VEGFR-2 is the
main receptor to mediate downstream actions of VEGF-A.
Ramucirumab has approximately eight times more efﬁcacyFigure 1 Mechanism of action of Ramucirumab. VEGF:
vascular endothelial growth factor, VEGFR: vascular endothelial
growth factor receptor, PKC: protein kinase C, MEK: MAPK/
extracellular signal-regulated kinase, ERK: extracellular signal-
regulated kinases.for binding this receptor than its natural ligand VEGF-A.
After binding to the receptor it induces conformational
changes as well as stearic hindrance for the ligands to bind [3].
Pharmacokinetic profile
Ramucirumab follows nonlinear pharmacokinetics. The clear-
ance decreases disproportionately with increasing dose and
number of infusion. Phase I study demonstrated decreasing
clearance as dose was increased from 2 to 8 mg/kg with little
change with further dose increment [1]. After single infusion
of 8 mg/kg dose and 10 mg/kg dose, the elimination T½ is
approximately 123 h and 110 h respectively. However, after
multiple infusion it increases to 318 h and 205 h respectively,
over all suggesting saturation kinetics.
The target trough level of ramucirumab has been found to
be approximately 20 lg/ml and the approximate doses of
ramucirumab that can maintain these trough are 6 mg/kg
every week, 8 mg/kg every two weeks, and 10 mg/kg adminis-
tered every three weeks.Evidence in various malignancies
Lung cancer
REVEL trial was a randomized phase III trial which showed
survival beneﬁt by ramucirumab in the patients with metastatic
NSCLC in second line setting in combination with docetaxel as
compared to docetaxel alone [4]. It randomized 1253 patients
in 1:1 ratio to receive docetaxel vs docetaxel and ramucirumab
combination. Median overall survival (OS) was 105 months
for 628 patients allocated combination and 91 months for
625 patients who received placebo plus docetaxel (hazard ratio
[HR] 086, 95% CI 075–098; p= 0023). Median progression
free survival (PFS) was 45 months for the combination group
compared with 30 months for the control group (HR-076,
95% CI 068–086; p< 00001). However, though the differ-
ence was statistically signiﬁcant, it was only 1.5 month for
PFS and 1.4 month for OS. In real life setting, this difference
might be even less. Furthermore, more uncertainty regarding
its regular prescription is expected when its side effect proﬁle
and cost effective is taken into consideration.
In a phase II trial, 140 patients were randomized 1:1 to
pemetrexed and carboplatin (or cisplatin) or ramucirumab
(10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once
every 3 weeks in ﬁrst line [5]. Treatment was given for 4 –6
cycles, and this was followed by a maintenance phase with
pemetrexed or ramucirumab and pemetrexed. The PFS was
7.2 months in ramucirumab arm compared to 5.6 months in
Ramucirumab: Boon or bane 135the other arm (HR: 0.75, p= 0.132). Disease control rate
(DCR) was signiﬁcantly better in ramucirumab arm (85.5%
vs 70.4% p= 0.032). No new or increased adverse events were
noted by addition of ramucirumab. Though ramucirumab
demonstrated clinical activity, it did not improve PFS
signiﬁcantly.
Another phase II single arm study, ramucirumab was com-
bined with paclitaxel and carboplatin for the treatment of state
IIB/IV NSCLC in 40 patients. 6-month PFS rate was 59.0%
and the overall response rate (ORR) was 55.0% with compa-
rable safety proﬁle to historical controls and there were no
treatment related deaths [6].
Gastroesophageal cancers
In phase III REGARD trial, patients with advanced gastric
or gastro-esophageal junction (GEJ) adenocarcinoma and
disease progression after ﬁrst-line platinum-containing or
ﬂuoropyrimidine-containing chemotherapy were randomly
assigned (2:1) to receive best supportive care plus either ramu-
cirumab 8 mg/kg or placebo, intravenously once every 2 weeks
[7]. Patients (N= 355) who received ramucirumab showed
improvement in PFS (2.1 vs 1.3 months, HR 0.48, p<
0.0001) and OS (5.2 vs 3.8 months, HR 0.78, p= 0.047).
Nonetheless, ORR was only 3% in both the arms. The only
toxicity more common in the ramucirumab arm was grade 3
hypertension in 8% of patients with rest of the toxicities being
comparable. Patients did not meet expected target of HR of
0.69 for OS.
Subsequently, RAINBOW study randomized 665 patients
to second-line paclitaxel with or without ramucirumab [8].
This study demonstrated signiﬁcantly superior OS in ramu-
cirumab/paclitaxel arm than paclitaxel alone arm (9.6 vs
7.4 months, p= 0.017); signiﬁcant improvement in ORR (28
vs 16%, p= 0.0001) and PFS were noticed as well (4.4 vs
2.9 months, p< 0.0001). Incidence of hypertension and grade
3 or 4 neutropenia (41 vs 19%) but not febrile neutropenia (3
vs 2%) was increased in the combination arm. So ramu-
cirumab became the ﬁrst antiangiogenic agent to show survival
advantage in advanced gastric cancer. Also, a subset analysis
showed signiﬁcantly better PFS, response rate in JapaneseTable 1 Comparison of antiangiogenic agents being tried in second
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FOLFOX4 ± vatalanibpatients. OS was also better in the Japanese group which did
not receive any post discontinuation therapy [9]. This suggest
inter-racial difference in treatment response and is important
in applying results from one population to another.
Another randomized phase II trial comparing folinic acid,
5-ﬂuorouracil, and oxaliplatin (FOLFOX) chemotherapy with
or without ramucirumab as ﬁrst-line therapy in esophageal
and gastric adenocarcinoma did not improve median PFS,
median OS, and response rate but showed improved DCR.
An unplanned subset analysis suggested patients with
GEJ/gastric tumors derived more beneﬁt than patients with
esophageal tumors [10]. The differential responses in gastric
versus esophageal tumor merits further study in
well-designed phase III trial.
Metastatic colorectal cancers (mCRCs)
Ramucirumab has been approved in metastatic colorectal can-
cer (mCRC) in combination with folinic acid, 5-ﬂuorouracil,
and irinotecan (FOLFIRI) in patients whose disease has pro-
gressed during or after therapy with bevacizumab, oxaliplatin,
and ﬂuoropyrimidine. The basis of approval comes from the
RAISE study [11]. It was a phase III trial that compared ramu-
cirumab plus FOLFIRI to placebo plus FOLFIRI in patients
with mCRC experiencing disease progression after prior ther-
apy. This trial was conducted in 1072 patients dividing them
equally into two arms. Study’s primary end point was OS
which was longer in the ramucirumab group than in the pla-
cebo group (13.3 months vs 11.7 months; p= 0.0219), con-
verting into 16% reduction of death in favor of
ramucirumab arm. PFS was also signiﬁcantly improved in
the ramucirumab group than in the placebo group (5.7 months
vs 4.5 months; p= 0.0005). However, addition of ramu-
cirumab also led to more grade 3 or higher toxicities predom-
inantly neutropenia (38.4% vs 23.3%), hypertension (11.2%
vs. 2.8%), and diarrhea (10.8% vs 9.7%). Table 1 summarizes
comparison of ramucirumab with other anti angiogenic drugs
being tried in second line setting in advanced CRC.
Ramucirumab has been tried in ﬁrst line setting in mCRC
in a phase II single arm trial. In a small study comprising 48
patients, ramucirumab was given in combination with-line in metastatic colorectal cancer.
PFS OS
5.7 vs 4.5 months, HR:
0.793, p= 0.0005,
13.3 vs 11.7 months, HR:
0.844, p= 0.0219
6.90 vs 4.67 months,
HR= 0.758, p= 0.0001
13.50 vs 12.06 months,
HR= 0.817, p= 0.0032
FOX4 7.3 vs 4.7 months,
HR= 0.61, p< 0.0001
For bevacizumab alone was
2.7 months
12.9 vs 10.8 months,
HR= 0.75, p= .0011
For bevacizumab alone was
10.2 months
6.8 vs 5.0 months,
HR= 0.70, p= 0.010
14.1 vs 15.5 months,
HR= 0.77; p = 0.043
5.7 vs 4.1 months, HR 0.68,
p< 0.0001
11.2 vs 9.8 months, HR 0.81,
p= 0.0062
1.9 vs 1.7 months,
HR= 0.49, p< 0.0001
6.4 vs 5.0 months,
HR= 0.77, p= 0.0052
5.6 vs 4.2 months,
HR= 0.83, p= 0.013
13.1 vs 11.9 months,
HR= 1.00, p= 0.957
136 P. TiwariFOLFOX-6 chemotherapy every 2 weekly [18].The inclusion
criteria included patients with mCRC, good performance sta-
tus and adequate organ function who had not received
chemotherapy for metastatic disease. Median PFS was
11.5 months (95% CI: 8.6–13.1 months). The ORR was
58.3% (95% CI: 43.21–72.39). The DCR was 93.8% (95%
CI: 82.8–98.7). Median OS was 20.4 months (95% CI: 18.5–
25.1 months). The most frequent grade 3–4 adverse events
included neutropenia (grade 3: 33.3%; grade 4: 8.3%), hyper-
tension (grade 3: 16.7%), and neuropathy (grade 3: 12.5%).
The trial showed good tolerability of ramucirumab and drug
discontinuation due to side-effects was not observed. Other
VEGF targeting drugs such as bevacizumab have multiple
adverse effects potentially effecting quality of life and treat-
ment continuation. Ramucirumab might score over them in
this regard.
Hepatocellular carcinoma (HCC)
A small phase II trial comprising 42 patients showed DCR of
69%, ORR of 9.5%, PFS of 4 months and OS of 12 months in
patients of advanced hepatocellular carcinoma (HCC). Inter-
estingly, median OS was 4.4 months (95% CI, 0.5–9.0) for
patients with Child-Pugh B cirrhosis versus 18.0 months
(95% CI, 6.1–23.5) for patients with Child-Pugh A cirrhosis
[19]. The reason for this difference is not known. However,
based on these results, ramucirumab might prove valuable in
patients with Child-Pugh A cirrhosis and merits further study
in this group of patients.
Phase III REACH trial showed nonsigniﬁcant increase in
OS (9.2 months on the ramucirumab arm compared to
7.6 months on the placebo arm [HR 0.866; 95% CI: 0.717–
1.046; p= 0.1391]) as second line treatment for patients whose
disease progressed on sorafenib [20]. Importantly, prespeciﬁed
subgroup with raised alpha-fetoprotein (AFP) P400 ng/mL
showed signiﬁcant improvement in survival. Median OS in this
subgroup of patients was 7.8 months in the ramucirumab arm
compared to 4.2 months in the placebo arm (HR 0.674; 95%
CI 0.508–0.895; p= 0.0059). Based on these REACH -2, a
new phase III trial is planned to assess beneﬁt of ramucirumab
in patient with raised AFP [21]. Also, by combining results of
above two trials, maximum beneﬁt might be observed in
patients with Child Pugh A with raised AFP.
Renal cell cancer
In a small study enrolling 39 patients with metastatic renal cell
cancer (mRCC), ramucirumab at dose of 8 mg/kg every
2 weekly was given after progression on tyrosine kinase inhibi-
tors or intolerable toxicity. The 12 week DCR was 64.1%
(95% CI, 47.2–78.8%).The ORR, median PFS, median OS
were 5.1% (95% CI, 0.6–17.3%), 7.1 months (95% CI, 4.1–
9.7 months), 24.8 months (95% CI, 18.9–32.6 months) respec-
tively. Grade 3 or higher adverse events that occurred inP5%
of patients included hypertension (7.7%) and proteinuria
(5.1%) [22]. Angiogenetic pathways play a major role in the
pathogenesis of RCC and thus ramucirumab might prove an
important adjunct in the management of mRCC. More impor-
tantly, another drug targeting VEGF pathways, Bevacizumab
was found to be more effective in combination with interferonalfa. Hence, ramucirumab should also be tried in combination
with other drugs which might further enhance its efﬁcacy.
Breast cancer
ROSE/TRIO-12 found that addition of Ramucirumab to doc-
etaxel did not improve PFS in randomized controlled phase III
trial conducted in cohort of 1144 HER2 negative patients with
unresectable, locally recurrent, or metastatic breast cancer.
This trial used ramucirumab in ﬁrst line setting for advanced
disease. Median PFS in combination was 9.5 months com-
pared to 8.2 months in docetaxel alone arm (HR 0.88;
p= 0.077). OS was also not different between the groups
(27.3 months versus 27.2 months) (HR, 1.01; p= 0.915) [23].
In breast cancer, three drugs targeting VEGF pathways
namely bevacizumab, sunitinib and ramucirumab failed to
show survival advantage [24,25]. The cause for failure of such
drugs in breast cancer remains to be elucidated. However, the
pace of development of drugs targeting angiogenesis in breast
cancer is deemed to slow down after failure of ramucirumab.
Epithelial ovarian malignancies
Ramucirumab was tried in patients with persistent or recurrent
epithelial ovarian, fallopian tube, or primary peritoneal carci-
noma who progressed after receiving platinum based
chemotherapeutic regimen. Primary endpoints were PFS at
6 months (PFS-6) and conﬁrmed ORR. Women with
platinum-free interval of <12 months with measurable disease
were eligible [26]. Out of 60 patients treated under this trial,
PFS-6 was 25.0% (95% CI: 14.7–37.9%). Partial response
(PR) was 5.0%, stable disease (SD) was 56.7%, and progres-
sive disease (PD) occurred in 33.3%.
Other malignancies
In prostate cancer, a phase II trial to compare ramucirumab in
combination with or without mitoxantrone and prednisolone
showed reasonable activity of this agent in patient with meta-
static castrate resistant prostate cancer who had progressed on
docetaxel. Sixty six patients were treated in three drug combi-
nation arm. Median PFS was 6.7 months (95% CI, 4.7–
8.3 months), median OS 13 months (95% CI 9.5–16 months).
Though the side-effects were similar to that reported in other
trials, it also showed grade 3 left ventricular dysfunction in
8% patients. This might be due to concomitant usage of mitox-
antrone, nevertheless warrants to be taken into consideration
in designing further trials [27].
In stage 4 malignant melanoma, ramucirumab with or with-
out dacarbazine was tested. With 102 patients overall, 52
patients were treated in the combination arm [28]. Median
PFS was 2.5 months in combination compared to 1.6 month.
PR was 4% and SD 48% in combination arm compared to
4% and 38% in dacarbazine only arm. Though results are
slightly better in the combination arm they are disappointing
to pursue further perusal.
Currently trials are ongoing in recurrent glioblastoma mul-
tiforme, urothelial malignancies, biliary tract tumors, pancre-
atic malignancies either in combination of chemotherapy,
immunotherapy or as single agent ramucirumab [29–33].






















Ramucirumab: Boon or bane 137Biomarker consideration
Data on pharmacodynamics from phase I study revealed
increase in VEGF-A concentration by 1.5–3.5 times of the pre-
treatment levels and fall in the levels of VEGFR 1 and 2 and
these changes were maintained till the time ramucirumab was
present in the body [1]. Similar to this, study in HCC also
showed increased circulating VEGF-A and placental growth
factor and decreased circulating sVEGFR-2 following initial
ramucirumab infusion [19]. However, it is yet not know,
whether this increase or decrease in serum biomarkers corre-
lates with therapeutic efﬁcacy.
Dosing and administration
Premedication with intravenous diphenhydramine before each
ramucirumab infusion is recommended. The drug is usually
given over one hour irrespective of the dose. Table 2 shows
dosing recommendation of ramucirumab. It is yet to be
approved for ﬁrst line therapy for any indication. It has been
used in second line in number of malignancies. It is continued
until disease progression or unacceptable toxicities.
Side-effects
Ramucirumab shows wide spectrum of toxicities (Table 3).
Importantly, the adverse effects are dose independent, though
studies using 10 mg/kg have reported higher incidence of
hypersensitivity reactions and asthenia compared to 8 mg/kg
dose. It carries boxed warning for hemorrhage, gastrointestinal
perforation, and impaired wound healing.
Trials of bevacizumab have demonstrated more toxicities
compared to trials of ramucirumab. Speciﬁcally, a meta-
analysis of 16 RCT including 10,217 patients revealed higher
mortality with bevacizumab with RR of 1.46 (95% CI, 1.09–
1.94; p= .01; incidence, 2.5% vs 1.7%) compared to
chemotherapy alone [34]. On the other hand, none of the trials
using ramucirumab have reported increase in mortality. In
addition, certain side-effects such as ﬁstula formation has been
documented in upto 4% patients treated with bevacizumab,
where as in the trials of ramucirumab, it is less than 1% [35].
In the RAINBOW trial, treatment discontinuation rate was
same with or without ramucirumab [8]. These studies suggest
that ramucirumab is more tolerable that other anti VEGF
agents. Precise mechanisms remain uncertain and a head to
head comparison with other antiangiogenic agents is lacking.Table 2 Dose and schedule used for approved indications.
Disease Regimen
Gastric cancer [8,9] Single agent or in combination with paclitaxel (ram
paclitaxel)
Treatment of advanced gastric or gastro-esophageal
after prior ﬂuoropyrimidine-or platinum-containing
NSCLC [5] In combination with docetaxel for metastatic NSCL
platinum-based chemotherapy (infuse prior to doce
mCRC [11] In combination with FOLFIRI for the treatment o
progressed on a ﬁrst-line bevacizumab-, oxaliplatin
(prior to FOLFIRI)
mCRC: metastatic colorectal cancer, NSCLC: non-small cell lung cancerFew of the other rare side-effects occurring in <5%
patients are thromboembolism and ascites.
Like other antiangiogenic drugs, hypertension is one of the
common side-effects of ramucirumab. Grade 3 hypertension
occurs in approximately 8% of patients. Nonetheless, it rarely
leads to treatment discontinuation. If patient already has
hypertension, it should be adequately controlled before treat-
ment initiation. Blood pressure should be monitored regularly
during treatment preferable at two weeks interval.
Arterial thrombotic events occurred in 2% compared to
none in placebo group in REGARD trial and including stroke
or myocardial infarction [7]. Drug should be permanently dis-
continued if such event is recorded.
Dosage modification
(1) Infusion related reactions: If infusion reactions are grade
1 or 2, it is advisable to add steroid and acetaminophen
for subsequent infusions along with reduction in infu-
sion rate by 50%. For all grade 3 and 4 infusion reac-
tions, it should be discontinued permanently.Dose and schedule
ucirumab prior to administration of
junction adenocarcinoma progressed on or
chemotherapy
8 mg/kg over 1 h IV
q2week
C with disease progression on or after
taxel)
10 mg/kg over 1 h, IV
q3week
f patients mCRC whose disease has
- and ﬂuoropyrimidine-containing regimen
8 mg/kg over 1 h, IV
q2week
, IV: intravenous, FOLFIRI: folinic acid, 5-ﬂuorouracil, irinotecan.
138 P. Tiwari(2) Wound healing: It should be discontinued at least four
weeks prior to surgery and should be started only after
wound is healed postoperatively. It should also be tem-
porarily discontinued in case of any wound healing
related complication during the course of therapy.
(3) Hypertension: Antihypertensive treatment is to be
started when treatment related hypertension develops.
If however, the hypertension becomes severe and
uncontrollable, ramucirumab should be permanently
discontinued.
(4) Proteinuria: Like many other drugs targeting angiogen-
esis, ramucirumab causes proteinuria. Hence urine pro-
tein measurement s should be obtained periodically.
Permanently discontinue for proteinuria >3 g/24 h.
(5) In case of events such as arterial thromboembolic events,
gastrointestinal perforation, or grade 3 or 4 bleeding,
ramucirumab should be permanently discontinued.
(6) Hepatic dysfunction: No modiﬁcation is indicated for
mild hepatic impairment. However for moderate to sev-
ere hepatic impairment (Child-Pugh B or C), caution
while using with close monitoring of liver functions is
preferable.
(7) Renal dysfunction: No data available about safely and
dose modiﬁcation of ramucirumab in case of renal
failure.
Concerns
(1) Cost-effectiveness of ramucirumab is still to be deter-
mined. Ramucirumab 8 mg/kg every 14 days has been
priced approximately $7000 per infusion which is higher
that bevacizumab. This increases cost of health care
many folds. Many centers do not use ramucirumab
because of prohibitive costs [36]. Determining drug
price is a big challenge in the present scenario and
we still have to go a long way to devise standard
recommendations
(2) Currently the studies on biomarkers are ongoing and we
still need more data to pinpoint the groups where ramu-
cirumab is more beneﬁcial and might also prove to be
more cost effective.
(3) Lack of activity with other VEGFR e.g. VEGFR1 and 3
which might act as bypass mechanisms causing resis-
tance to ramucirumab. Combination strategies targeting
alternate pathways might prove more effective and can
be tried in future studies.
(4) Requirement of different subset of investigation for
response assessment is need of the hour as far as antian-
giogenic agents are concerned. Decrease in angiogenesis
may not always reﬂect in decrease in size of tumors.
Investigations like dynamic contrast enhanced magnetic
resonance imaging can measure changes in blood ﬂow,
tumor volume and might be more accurate in assessing
treatment response. However, the ﬁeld of imaging bio-
marker is still evolving and more evidence is needed
before any clear cut recommendation can be made
regarding their incorporation in response assessment.
(5) Ramucirumab is more tolerable than other antiangio-
genic agents. However, it does cause gastrointestinal
perforation, arterial thromboembolism, hemorrhageand ﬁstula formation. Thus it puts additional burden
on the heath care, leading to permanent discontinuation
of the drug. For the drug, which has shown only modest
survival beneﬁts, these side-effects become a major fac-
tor in determining use.
(6) Impact over quality of life due to ramucirumab is still to
be determined. Since studies have shown only limited
improvement in survival while increasing cost of care
by addition of this drug, it becomes important to carry
out quality of life analysis in these and subsequent stud-
ies which will help us to potentiate decision regarding
the use of this drug.
Conclusion
Ramucirumab has found ﬁrm footing in the current therapeu-
tic landscape for many advanced cancers. Though, it shows
class side-effects of drugs targeting angiogenesis, there is accu-
mulating evidence that it might be more tolerable than other
drugs in this class. However, it is a drug devoid of signiﬁcant
gains as far as survival is concerned. Over all, more evidence
on cost effectiveness and quality of life is needed to clarify
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